Illumina Advances Precision Oncology And Gains Speed In Infectious Disease
Greater Use Of Genomics For Surveillance During COVID-19 Has Shown That Scientists Will No Longer Fight Blind In Infectious Disease Control
Illumina’s moves into infectious disease testing and further into the clinical setting have been accelerated by the pandemic. The genomic sequencing company is also fast expanding its companion diagnostics oncology partnerships.
You may also be interested in...
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the first day of the meeting.
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
The total addressable market for genomics-based infectious disease testing has expanded in recent months, says Illumina, after becoming the first company to receive a US EUA for a next-generation sequencing-based COVID-19 test. It came amid a raft of innovation activity and tuck-in M&A for the San Diego company.